S046 What's New in Dermatopathology
DESCRIPTION
This symposium provides information regarding advances in key areas of dermatopathology. Cutaneous neoplasia, inflammatory skin disease, molecular techniques, computer assisted diagnosis/artificial intelligence, translational research, and cutaneous infections will be covered. Attendees will leave the session with updated knowledge in dermatopathology.
LEARNING OBJECTIVES
Describe new advances in cutaneous neoplasia, including melanocytic tumors and adnexal neoplasms
Discuss recent developments in diagnosing inflammatory skin disease and cutaneous drug reactions
Describe recent developments in artificial intelligence in the field of dermatopathology
SCHEDULE
1:00 PM
What's new in inpatient dermatology?
Kiran Motaparthi, MD, FAAD
1:20 PM
What's new in digital pathology?
Corey J. Georgesen, MD, FAAD
1:40 PM
What's new in oncodermatology?
Anisha Patel, MD, FAAD
2:00 PM
Q&A
Anisha Patel, MD, FAAD, Corey J. Georgesen, MD, FAAD, Kiran Motaparthi, MD, FAAD
2:10 PM
What's new in adnexal neoplasms?
Jeffrey P. North, MD, FAAD
2:30 PM
What's new in keratinocytic carcinoma?
Kenneth Y. Tsai, MD, PhD, FAAD
2:50 PM
Q&A
Jeffrey P. North, MD, FAAD, Kenneth Y. Tsai, MD, PhD, FAAD
3:00 PM
What's new in viral infectious diseases?
Travis W. Vandergriff, MD, FAAD
3:20 PM
What's new in nail pathology?
Molly A. Hinshaw, MD, FAAD
3:40 PM
What's new in rashes?
Ronald P. Rapini, MD, FAAD
DIRECTOR
Anisha Patel, MD, FAAD
UT MD Anderson Cancer Center
SPEAKERS
Corey J. Georgesen, MD, FAAD
Molly A. Hinshaw, MD, FAAD
University of Wisconsin School of Medicine and Public Health
Kiran Motaparthi, MD, FAAD
University of Florida College of Medicine
Jeffrey P. North, MD, FAAD
Ronald P. Rapini, MD, FAAD
Kenneth Y. Tsai, MD, PhD, FAAD
Travis W. Vandergriff, MD, FAAD
DISCLOSURES
Corey J. Georgesen, MD, FAAD
No financial relationships exist with ineligible companies.
Molly A. Hinshaw, MD, FAAD
BiaCure Therapies Inc – Founder(Stock);
Kiran Motaparthi, MD, FAAD
No financial relationships exist with ineligible companies.
Jeffrey P. North, MD, FAAD
Johnson & Johnson Pharmaceutical Research & Development – Consultant (1099 relationship)(Fees);
Anisha Patel, MD, FAAD
Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); FBIO Acquisition Corp LII – Consultant (1099 relationship)(Stock); Hoth Therapeutics – Investigator(Grants/Research Funding); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);
Ronald P. Rapini, MD, FAAD
No financial relationships exist with ineligible companies.
Kenneth Y. Tsai, MD, PhD, FAAD
3CC - Third Culture Capital – Stockholder(No Compensation Received); Altos Labs – Consultant (1099 relationship)(Fees); Ankyra Therapeutics – Independent Contractor(Grants/Research Funding); APIS Assay Technologies – Independent Contractor(Grants/Research Funding); DX Biosciences, Inc – Consultant(Stock Options); Incyte Corporation – Investigator(Grants/Research Funding); NFlection Therapeutics, Inc – Consultant(Fees); Regeneron Pharmaceuticals Inc – Advisory Board(Fees); UpToDate – Independent Contractor(Fees); Verrica Pharmaceuticals Inc – Independent Contractor(Fees);
Travis W. Vandergriff, MD, FAAD
Elsevier Inc. – Independent Contractor(Honoraria);